Table 3 Treatment-related adverse events based on CTCAE 5.0
Adverse events | RT + PD1, N = 37 (%) | TACE + sorafenib, N = 41(%) | P value | |||
|---|---|---|---|---|---|---|
|  | Any grade (%) | Grade 3–4 (%) | Any grade (%) | Grade 3–4 (%) | Any grade | Grade 3–4 |
Increased AST | 20(54.05) | 2(5.41) | 38(92.68) | 24(58.54) |  < 0.001 |  < 0.001 |
Increased ALT | 19(51.35) | 2(5.41) | 33(80.49) | 15(36.59) | 0.008 | 0.001 |
Hand-foot skin reaction | 0(0) | 0(0) | 22(53.66) | 6(14.63) |  < 0.001 | 0.027 |
Decreased hemoglobin | 33(89.19) | 5(13.51) | 28(68.29) | 2(4.88) | 0.031 | 0.247 |
Decreased albumin | 30(81.08) | 0(0) | 37(90.24) | 1(2.44) | 0.333 | 1.000 |
Decreased white blood cell | 28(75.68) | 3(8.11) | 12(29.27) | 1(2.44) |  < 0.001 | 0.341 |
Increased blood bilirubin | 20(54.05) | 1(2.70) | 16(39.02) | 1(2.44) | 0.256 | 1.000 |
Decreased platelet count | 19(51.35) | 8(21.62) | 14(34.115) | 5(12.20) | 0.169 | 0.364 |